MGMT and glioblastoma: The proportion of patients receiving MGMT testing in our cohort (74.6%) is a significant increase over the proportion reported by Lee et al. (13%), who analyzed data from the 2010–2012 NCDB among patients with histologically-diagnosed GBM [17].